Page 131 - 2018_10-Haematologica-web

IMiDs block megakaryocytic maturation
12. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-2132.
13. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
14. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplan- tation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
15. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
16. Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative of thalido- mide (IMiD CC-4047) induces a shift in lin- eage commitment by suppressing erythro- poiesis and promoting myelopoiesis. Blood. 2005;105(10):3833-3840.
17. Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010; 115(3):605-614.
18. Poirault-Chassac S, Six E, Catelain C, et al. Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation. Blood. 2010;116(25):5670-5678.
19. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93(9):2867-2875.
20. Cantor AB, Katz SG, Orkin SH. Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation. Mol Cell Biol. 2002;22(12):4268-4279.
21. Wilkinson-White L, Gamsjaeger R, Dastmalchi S, et al. Structural basis of simul- taneous recruitment of the transcriptional regulators LMO2 and FOG1/ZFPM1 by the transcription factor GATA1. Proc Natl Acad Sci USA. 2011;108(35):14443-14448.
22. Tsang AP, Visvader JE, Turner CA, et al. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA- 1 in erythroid and megakaryocytic differen- tiation. Cell. 1997;90(1):109-119.
23. Takayama M, Fujita R, Suzuki M, et al. Genetic analysis of hierarchical regulation
for Gata1 and NF-E2 p45 gene expression in megakaryopoiesis. Mol Cell Biol. 2010; 30(11):2668-2680.
24. Wang X, Crispino JD, Letting DL, Nakazawa M, Poncz M, Blobel GA. Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. EMBO J. 2002;21(19):5225-5234.
25. Muntean AG, Pang L, Poncz M, Dowdy SF, Blobel GA, Crispino JD. Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidiza- tion. Blood. 2007;109(12):5199-5207.
26. Furukawa Y, Kikuchi J, Nakamura M, Iwase S, Yamada H, Matsuda M. Lineage-specific regulation of cell cycle control gene expres- sion during haematopoietic cell differentia- tion. Br J Haematol. 2000; 110(3):663-673.
27. Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301-305.
28. Lu G, Middleton RE, Sun HH, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305-309.
29. Dijon M, Bardin F, Murati A, Batoz M, Chabannon C, Tonnelle C. The role of Ikaros in human erythroid differentiation. Blood. 2008;111(3):1138-1146.
30. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion- dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with kary- otypes other than deletion 5q. Blood. 2008; 111(1):86-93.
31. Li Z, Godinho FJ, Klusmann JH, Garriga- Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutat- ed leukemogenic transcription factor GATA1. Nat Genet. 2005;37(6):613-619.
32. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syn- drome. Nat Genet. 2002;32(1):148-152.
33. Choi JK. Hematopoietic disorders in Down syndrome. Int J Clin Exp Pathol. 2008;1 (5):387-395.
34. Lorsbach RB. Megakaryoblastic disorders in children. Am J Clin Pathol. 2004;122 Suppl(S33-46).
35. Shivdasani RA, Rosenblatt MF, Zucker-
Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independ- ent of the actions of thrombopoietin/ MGDF in megakaryocyte development. Cell. 1995;81(5):695-704.
36. Lecine P, Villeval JL, Vyas P, Swencki B, Xu Y, Shivdasani RA. Mice lacking transcrip- tion factor NF-E2 provide in vivo validation of the proplatelet model of thrombocy- topoiesis and show a platelet production defect that is intrinsic to megakaryocytes. Blood. 1998;92(5):1608-1616.
37. Papetti M, Wontakal SN, Stopka T, Skoultchi AI. GATA-1 directly regulates p21 gene expression during erythroid dif- ferentiation. Cell Cycle. 2010;9(10):1972- 1980.
38. Orford KW, Scadden DT. Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet. 2008; 9(2):115-128.
39. Fouquet G, Tardy S, Demarquette H, et al. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer. 2013; 119(20):3680-3686.
40. Malinge S, Thiollier C, Chlon TM, et al. Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood. 2013; 121(13):2440-2451.
41. Kronke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523(7559):183-188.
42. Schneider RK, Adema V, Heckl D, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26(4):509-520.
43. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet. 2000; 24(3):266-270.
44. Badros AZ. Lenalidomide in myeloma--a high-maintenance friend. N Engl J Med. 2012;366(19):1836-1838.
45. Zhu J, Chin K, Aerbajinai W, Trainor C, Gao P, Rodgers GP. Recombinant erythroid Kruppel-like factor fused to GATA1 up-reg- ulates delta- and gamma-globin expression in erythroid cells. Blood. 2011;117(11): 3045-3052.
haematologica | 2018; 103(10)
1697